电邮这篇文章 Modern view on the place of riociguat in the treatment of pulmonary hypertension
- 作者: Valieva ZS1, Taran IN1, Martynyuk TV1, Chazova IY.1
-
隶属关系:
- National Medical Research Center of Cardiology, Ministry of Health of Russia
- 期: 卷 90, 编号 4 (2018)
- 页面: 55-59
- 栏目: Editorial
- URL: https://bakhtiniada.ru/0040-3660/article/view/32470
- ID: 32470
如何引用文章
全文:
详细
Current research is aimed at studying the fundamental therapeutic targets and discovering new drugs acting on previously set targets. Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) was the use of phosphodiesterase type 5 inhibitors (PDE-5 inhibitors), such as sildenafil. In September 2014, the first member of sGC stimulators riociguat was licensed in Russia. In the paper, the results of 5 multicenter studies (CHEST-1 and PATENT-1, CHEST-2 and PATENT-2, RESPITE), which reflect the effectiveness and safety of mono - and combination therapy with riociguat in patients suffer from some forms of pulmonary arterial hypertension, and patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTPH), as well as the possibility of optimizing therapy in patients with PAH using iPDE-5 -> riociguat switching was reviewed. It also provides information on the recently launched international registries EXPERT CTEPH; new REPLACE study was announced.
作者简介
Z Valieva
National Medical Research Center of Cardiology, Ministry of Health of Russiaк.м.н., м.н.с. лаб. легочной гипертензии отд. гипертонии Moscow, Russia
I Taran
National Medical Research Center of Cardiology, Ministry of Health of Russiaд.м.н., в.н.с., руководитель лаб. легочной гипертензии отд. гипертонии Moscow, Russia
T Martynyuk
National Medical Research Center of Cardiology, Ministry of Health of Russia
Email: trukhiniv@mail.ru
д.м.н., руководитель отд. легочной гипертензии и заболеваний сердца Института клинической кардиологии им. А.Л. Мясникова НМИЦ кардиологии, проф. каф. кардиологии ФДПО РНИМУ им. Н.А. Пирогова Moscow, Russia
I Chazova
National Medical Research Center of Cardiology, Ministry of Health of Russiaакадемик РАН, проф., ген. директор НМИЦ кардиологии, директор Института клинической кардиологии, руководитель отд. гипертонии Moscow, Russia
参考
- Чазова И.Е., Мартынюк Т.В., редакторы. Легочная гипертензия. Москва: Практика; 2015. 928 с.
- Schermuly R.T, Stasch J.P, Pullamsetti S.S, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008;32:881-91. doi: 10.1183/09031936.00114407
- Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785-92. doi: 10.1183/09031936. 00039808
- Инструкция по применению лекарственного препарата для медицинского применения Адемпас. Регистрационный номер: ЛП-002639. От 05.10.2017
- Ghofrani H.A, D’Armini A.M, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Eng J Med. 2013;369:319-29. doi: 10.1056/NEJMoa1209657
- Ghofrani H.A, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Eng J Med. 2013;369:330-40. doi: 10.1056/NEJMoa1209655
- Государственный регистр лекарственных средств. Доступно по ссылке: http://www.grls.rosminzdrav.ru
- European Medicines Agency. Available at: http://www.ema.europa.eu
- Rubin L.J, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z.C, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long - term extension study (PATENT-2). Eur Respir J. 2015 May;45(5):1303-13. doi: 10.1183/09031936.00090614
- Ghofrani H.A, Grimminger F, Grünig E, Huang Y, Jansa P, Jing Z.C, et al. Predictors of long - term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open - label, randomised, long - term extension trial. Lancet Respir Med. 2016;4:361-71. doi: 10.1016/S2213-2600(16)30019-4
- Ghofrani H.A, Galiè N, Friedrich Grimminger F, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2013;369:330-40. doi: 10.1056/NEJMoa1209655
- Simonneau G, D'Armini A, Ghofrani H, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1-year results from the CHEST-2 long - term extension study. Chest. 2013;144:1023A. doi: 10.1378/chest.1783236
- Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67-119. doi: 10.1093/eurheartj/ehv317. Available at: http://eurheartj.oxfordjournals.org/content/ehj/37/1/67.full.pdf
- Ghofrani H.A, D'Armini A.M, Grimminger F, et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med. 2013; 369:319-29 + Protocol + Sup. appendix. doi: 10.1056/NEJMoa1209657
- Simonneau G, D'Armini A.N, Ghofrani H-A, et al. Predictors of long - term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open - label, randomised, long - term extension trial. Lancet Respir Med. 2016;4:372-80. doi.org/10.1016/S2213-2600(16)30022-4
- Simonneau G, D'Armini A.N, Ghofrani H-A, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long - term extension study (CHEST-2). Eur Respir J. 2015;45:1293-302. doi: 10.1183/09031936.00087114
- Хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации. Российское медицинское общество по артериальной гипертонии. Доступно по ссылке: http://cr.rosminzdrav.ru/#!/ schema/137
- Klinger J.R, Abman S.H, Gladwin M.T. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188:639-46. doi: 10.1164/rccm.201304-0686PP
- Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005;99(1):91-5. doi: 10.1016/j.ijcard.2003.12.023
- Leuchte H.H, Schwaiblmair M, Baumgartner R.A, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004;125:580-6. doi: 10.1378/chest.125.2.580
- Stasch J.P, Pacher P, Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263-73. doi: 10.1161/CIRCULATIONAHA.110. 981738
- Hoeper M.M, Simonneau G, Corris P.A, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50:1602425. doi: 10.1183/13993003.02425-2016
- EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (EXPERT). ClinicalTrials.gov Identifier: NCT02092818. Available at: https://clinicaltrials.gov/ct2/show/ NCT02092818
- Klose H, et al. Riociguat For The Treatment Of Pulmonary Hypertension: Safety Data From The Expert Registry. Am J Respir Crit Care Med. 2017;195:A2292. Available at: https://www.atsjournals.org/doi/ pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2292
- A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries (EMEA CTEPH). ClinicalTrials.gov Identifier: NCT02637050. Available at: https://clinicaltrials.gov/ct2/show/NCT02637050
- Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (REPLACE). ClinicalTrials.gov Identifier: NCT02891850. Available at: https://clinicaltrials.gov/ct2/show/ NCT02891850
补充文件
